Evidence map›Paper›PMID 41634663›Full record

ReviewMolecular cancer2026

Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.

Shi Dong, Taiyuan Li

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. In Vitro Anti-Breast Cancer Effects ofInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shi DongDepartment of General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, China.
Taiyuan LiDepartment of General Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, China. jylitaiyuan@sina.com.

Funding

National Natural Science Foundation of China 81860519
6 · The paper itself

Abstract

Metabolism is a general term for an ordered series of chemical reactions used to maintain life, and the maintenance of normal cellular activities cannot be separated from metabolism, which is the most basic feature of life. However, metabolic alterations have a dual role. In normal cells, metabolic dysregulation predisposes them to impaired energy acquisition, senescence and even apoptosis. In contrast, metabolic remodeling in tumor cells is advantageous for cancer cell growth and proliferation, driving tumor development and becoming a hallmark of cancer. The inherent heterogeneity and plasticity of many tumor cells themselves are often accompanied by unique alterations in energy metabolism that allow them to survive even in harsh environments where resources are scarce. Notably, tumor cells do not operate in isolation; their metabolic reprogramming is tightly intertwined with metabolic crosstalk and collaborative adaptations involving other components within the tumor microenvironment. Among these metabolic pathways, glycolysis remains the dominant metabolic pathway driving tumor growth and microenvironmental remodeling, even under oxygen-sufficient conditions. Additionally, amino acid, lipid, and polyamine metabolism have been identified as a metabolic regulators that support cancer cell growth, influencing the fate and function of other cells in the microenvironment through metabolite exchange. Targeting cancer metabolism and its interactions with the microenvironment has thus emerged as a promising strategy for treating various malignancies. This article systematically reviews the redistribution of metabolic activities during cancer progression, encompassing both cell-autonomous metabolic reprogramming and microenvironment-mediated metabolic synergy and adaptation. The aim is to provide novel insights and therapeutic strategies for the comprehensive treatment of cancer.

Indexed as

Metabolic ReprogrammingNeoplasmsSignal TransductionAnimalsAntineoplastic AgentsEnergy MetabolismHumansMetabolic Networks and PathwaysMolecular Targeted TherapyTumor MicroenvironmentAntineoplastic AgentsCancerGlucoseGlutamineLipidMetabolic reprogrammingPolyamineTumor microenvironment

Identifiers

PMID41634663
PMCPMC12967016

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.